Bausch Health Announces Expanded Public Drug Plan Listings for UCERIS® in Canada

Bausch Health, Canada Inc., part of Bausch Health Companies Inc., has announced additional public drug plan listings for PrUCERIS® (budesonide) aerosol foam for treating mild to moderate distal ulcerative colitis in adults. The drug is now accessible through public drug plans in Alberta, Prince Edward Island, and Newfoundland and Labrador, as well as federal plans for Indigenous people and Veterans Affairs Canada.

Previously this year, UCERIS was added to drug plans in Ontario, Quebec, Saskatchewan, New Brunswick, and Nova Scotia. Cees Heiman, Senior VP for Europe and Canada at Bausch Health, expressed satisfaction with the rapid inclusion of UCERIS in various public drug plans following negotiations.

UCERIS, available by prescription since September 2023, is the only glucocorticosteroid rectal foam in Canada for inducing remission in distal ulcerative colitis. Studies indicate a significant preference for the foam formulation due to better tolerability and ease of application.